Imho, you need to take a look at a 3 year montly chart of this company. In April of 2011, the stock was selling for $4 per share. The chart shows the pps steadily going up a long flight of stairs. It jumps on news and holds steady until the next news release. The release of the preliminary results of the Pilar study is a good example.
If you are following the company closely, it is hard not to conclude that there are a series of positive news releases that are almost certain to occur over the next year. Lymph nodes. Endomitriosis. The publishing of the final results of the Pilar study. Futher international partnerships.
There is one risk. Will they successfully implement the domestic sales effort for Pinpoint and Lunar. The company is aggressively expanding its sales force which has an expensive cost. There is an old Wall Street addage that goes......On Wall Street, money flows from the impatient to the patient. I believe that very much applies to this stock.